Universal screening of pregnant women is feasible and has led to immunisation in nearly all identified cases in Denmark. As a consequence of the study the National Board of Health has made universal HBsAg screening of pregnant women permanent in the country.
On the occasion of the European Respiratory Society’s (ERS) Annual Congress in Amsterdam, ECDC and ERS today introduce a draft of the EU Standards for Tuberculosis Care (ESTC).
The ERS Annual Congress brings together the world's respiratory experts and professionals to meet, exchange views and share knowledge covering all aspects of respiratory medicine, novelties and most recent data presentations.
The WHO Regional Committee for Europe approved a new action plan to tackle multi-drug resistant and extensively drug resistant tuberculosis (M/XDR-TB) today. This is another milestone in the European efforts to secure strong tuberculosis prevention and control across the region.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
ECDC was pleased that the Government of Romania extended an invite to meet health care workers who are working with the Roma population. ECDC Director, Marc Sprenger, as head of the delegation shares three lesson.
During a recent country visit to Romania, ECDC emphasised the key issues for TB control. Following the invitation of the Romania Ministry of Health, ECDC disease experts, led by ECDC Director Marc Sprenger, visited the Marius Nasta Institute, which historically has been in the front line for TB control in the country.
IGRAs are increasingly being considered for the diagnosis of LTBI, as a replacement to the TST, including travel medicine. As with the TST, many uncertainties remain with regard to the efficacy of the IGRAs. It is therefore essential to secure an accurate understanding of these assays‘ known efficacy, so that they be optimally used and only in context with proven effect.